

## PRESS RELEASE

June 2023

Deeptech Development Grant of € 1.5M  
signed with Bpifrance

**New support from Bpifrance for €1.5M, covering the GMP production of the Drug Substance OptPA, has been obtained, increasing the proportion of funds secured in our 23M€ Series A.**

The deeptech development grant finances companies carrying out deeptech technological innovation projects, involving industrial research and/or experimental development work, to develop innovative products and processes with concrete prospects for industrialisation and marketing. With its innovation based on NANOp2Lysis® technology, a platform incorporating a breakthrough technology enabling active enzymes to be vectorised (in a delivery system) with a high concentration and clinical quality, O2L-001 is the first product to emerge from this platform. O2L-001 offers new hope for patients suffering from cerebral haemorrhage, an unmet medical need whose outcome is dramatic in socio-economic terms, with more than 50% mortality at one year and half of survivors suffering from severe disability and dependence.

At the end of May 2023, Op2Lysis was awarded a Deeptech Development Grant (ADD) to manufacture the clinical batch of OptPA, the active substance in O2L-001, for phase 1/2 in patients suffering from cerebral haemorrhage. This activity, made possible by the scale-up of the manufacturing processes and the success of the CMC development, will be performed in 2024.

In addition to European (EIC accelerator) and Walloon (DGO6) supports, this financial instrument demonstrates the attractiveness and traction of the company, its strategy and its technology. More than 40% of the €23m we are currently raising, has now been secured to complete the O2L-001 and NANOp2Lysis® program, which is well on its way to achieving clinical phase 1/2.

*"It is excellent news to receive the support of Bpifrance for this important stage, which is the manufacture of our clinical batches. Bpifrance is a long-standing partner and we are delighted to receive this support. We are attractive in this post-COVID period and it is important that this information is visible. This support comes at an important time, given that we have successfully completed the industrialisation of OptPA and O2L-001. The ADD will complement our de-risking strategy for new investors" - Christophe Gaudin, co-founder of Op2Lysis.*

Boulogne-Billancourt, 05/06/2023

For further information, please contact :

**Christophe Gaudin, CEO**

 [christophe.gaudin@op2lysis.com](mailto:christophe.gaudin@op2lysis.com)  
 +33 607 979 008  
 [www.op2lysis.com](http://www.op2lysis.com)

**Jérôme Parcq, CSO**

 [jerome.parcq@op2lysis.com](mailto:jerome.parcq@op2lysis.com)  
 +33 615 270 969  
<https://www.linkedin.com/company/op2lysis>

About Op2Lysis - [www.op2lysis.com](http://www.op2lysis.com)

 Op2Lysis is a biotechnology company dedicated to the development of breakthrough therapeutic solutions for cerebrovascular thrombotic diseases. With its first drug, O2L-001, Op2Lysis develops the first medical treatment for deep and large cerebral haemorrhage, the most debilitating form of stroke. Op2Lysis aims to become a leader in the development of treatments for all forms of cerebral haemorrhage. Op2Lysis benefits from the dynamic ecosystems of the regions in which the company is located, Caen and Liège

**Op2Lysis SAS:** 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France  
GIP Cyceron, Boulevard Henri Becquerel, 14000 Caen, France

**Op2Lysis Development SA :** Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

#### **About NANOp2Lysis®**

NANOp2Lysis® is Op2Lysis' proprietary platform, combining four key elements for the development of breakthrough therapeutic solutions: a unique vectorisation technology; industrial know-how to produce clinical-quality batches; preclinical expertise including predictive and translational models, a first in this field; and regulatory expertise to accelerate market access.

#### **About O2L-001**

O2L-001 is a locally administered treatment designed to liquefy the intracerebral haematoma that has formed following a cerebral haemorrhage, in order to evacuate it and reduce its deleterious mass effect. O2L-001 has been specifically designed for large, deep haematomas. Its development is based on documented clinical proof of concept (MISTIE programme), including the demonstration of a robust association between reduction in blood volume and reduction in disability. The competitive advantages of O2L-001 observed in the best translational models indicate the potential for major efficacy and increased safety in this therapeutic indication. O2L-001 should radically change practice in this therapeutic indication.

#### **About Deeptech Development Support (« Aide au Développement Deeptech – ADD »)**

Deeptech development support is a tool offered by Bpifrance to finance expenditure relating to the research and development phases of a disruptive innovation project prior to its industrial and commercial launch. This support (grant and reimbursable debt) is eligible for projects linked to disruptive innovation and deeptech start-ups (close links with the world of research, high added-value innovation, strong intellectual property).